EMPIRIC TREATMENT OF COMMUNITY-ACQUIRED PNA IN NON-ICU PATIENTS^

Community-acquired pneumonia is defined as pneumonia acquired outside of hospitals.

HMS PREFERRED THERAPY for patients with non-life threatening pencillin allergy (without anaphylaxis, angioedema, hives)	ALTERNATIVE BUT HMS NON-PREFERRED Preferred for patients with cephalosporin allergy, allergy to both macrolides and doxycycline/tetracycline, or severe penicillin allergy.
Ampicillin-Sulbactam 3gm IV q6h **OR** Ceftriaxone 1gm IV q24h **PLUS** Azithromycin 500mg IV/PO x 1 day, then 250mg q24h x 4 days* **OR** Clarithromycin 500mg PO BID **OR** Doxycycline 100mg PO BID	Levofloxacin 750 mg PO/IV Once Daily **OR** Moxifloxacin 400mg PO/IV Once Daily

*Consider substituting doxycycline for azithromycin in patients with a macrolide allergy or at risk for prolonged QT interval.

ORAL STEP-DOWN THERAPY WHEN NO ETIOLOGIC PATHOGEN IDENTIFIED FOR CAP**

Amoxicillin (1g PO 3 x daily)
Amoxicillin/clavulanate (2g PO 2 x daily)
Cefpodoxime (200mg PO 2 x daily)
Cefdinir (300mg PO 2 x daily)
Cefditoren (400mg PO 2 x daily)
Cefuroxime (500mg PO 2 x daily)

+/-

Azithromycin, Doxycyline, or Clarithromycin
(see dosing above)

Alternatives: Levofloxcin or Moxifloxacin in setting of severe PCN allergy

^Excludes patients with a previous culture positive for MRSA or resistant gram-negative organism in the past year OR patients with severe CAP who were hospitalized and received IV antibiotics in the previous 90 days.
**Suggested dosing only. Please individualize based on renal function or other pertinent clinical factors.
Anaerobic coverage is not routinely warranted in non-critically ill patients with aspiration pneumonia.
For more detail about these guidelines, please see the Treatment of Community-Acquired Pneumonia Guidelines published by HMS.

THERAPY DURATION & ORAL STEP-DOWN THERAPY RECOMMENDATIONS FOR PATIENTS WITH CAP

DEFINTIONS OF UNCOMPLICATED CAP & COMPLICATED CAP	
UNCOMPLICATED CAP	Patients who do not meet any of the criteria below.
COMPLICATED CAP	Patients with structural lung disease (e.g. bronchiectasis, pulmonary fibrosis, interstitial lung disease); moderate/severe COPD (excluding COPD exacerbation without pneumonia); documented pneumonia with MRSA, MSSA, or Pseudomonas (or other non-fermenter/gram negative pneumonia); or those who are immunosuppressed.

DURATION OF ANTIMICROBIAL THERAPY (INCLUDES IV & ORAL)	
UNCOMPLICATED CAP	**5 Days** if patient is afebrile for 48 hours and has ***no more than one*** sign of clinical instability* by day 5 of treatment Therapy can be continued for patients who are febrile or clinically unstable* on day 5 of treatment
COMPLICATED CAP	**7 Days** if patient is afebrile for 48 hours and has ***no more than one*** sign of clinical instability* by day 7 of treatment (Note: Azithromycin duration should be no more than 5 days) Therapy can be continued for patients who are febrile or clinically unstable* on day 7 of treatment

****Signs of Clinical Instability:*** O2 saturation < 90% or new oxygen requirement, HR > 100 bpm, RR > 24 bpm, SBP <90 mmHg, altered mental status (different than baseline)

Blue Cross Blue Shield Blue Care Network of Michigan

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

HMS MICHIGAN HOSPITAL MEDICINE SAFETY CONSORTIUM

Support for HMS is provided by Blue Cross and Blue Shield of Michigan and Blue Care Network as a part of the BCBSM Value Partnerships program. Although Blue Cross Blue Shield of Michigan and HMS work collaboratively, the opinions, beliefs, and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.